202
Participants
Start Date
March 31, 2013
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
sarilumab SAR153191 (REGN88)
Pharmaceutical form: solution Route of administration: subcutaneous
tocilizumab
Pharmaceutical form: solution Route of administration: intravenous
hydroxychloroquine
Dispensed according to local practice.
methotrexate
Dispensed according to local practice.
sulfasalazine
Dispensed according to local practice.
leflunomide
Dispensed according to local practice.
subcutaneous placebo
Pharmaceutical form: solution Route of administration: subcutaneous
intravenous placebo
Pharmaceutical form: solution Route of administration: intravenous
Investigational Site Number 348014, Budapest
Investigational Site Number 348022, Budapest
Investigational Site Number 348016, Kistarcsa
Investigational Site Number 348021, Esztergom
Investigational Site Number 056010, Leuven
Investigational Site Number 578006, Tønsberg
Investigational Site Number 032004, San Miguel de Tucumán
Investigational Site Number 032005, San Miguel de Tucumán
Investigational Site Number 578010, Kristiansand
Investigational Site Number 348009, Szolnok
Investigational Site Number 348015, Szombathely
Investigational Site Number 233010, Tallinn
Investigational Site Number 246010, Riihimäki
Investigational Site Number 484001, México, D.F.
Investigational Site Number 203011, Prague
Investigational Site Number 233002, Tallinn
Investigational Site Number 380005, Genova
Investigational Site Number 840062, Reading
Investigational Site Number 840013, Wheaton
Investigational Site Number 376010, Haifa
Investigational Site Number 840048, Miami
Investigational Site Number 840153, Aventura
Investigational Site Number 840033, Fort Lauderdale
Investigational Site Number 484008, Durango
Investigational Site Number 840155, Palm Harbor
Investigational Site Number 840152, Huntsville
Investigational Site Number 484035, León
Investigational Site Number 724021, Santander
Investigational Site Number 724022, Seville
Investigational Site Number 484036, Zapopan
Investigational Site Number 203009, Liberec
Investigational Site Number 840150, Lansing
Investigational Site Number 380002, Florence
Investigational Site Number 376011, Tel Aviv
Investigational Site Number 840074, Mesquite
Investigational Site Number 840022, Dallas
Investigational Site Number 840156, Dallas
Investigational Site Number 840038, Austin
Investigational Site Number 840151, Colorado Springs
Investigational Site Number 484009, Mérida
Investigational Site Number 643020, Moscow
Investigational Site Number 643001, Moscow
Investigational Site Number 643002, Moscow
Investigational Site Number 643031, Moscow
Investigational Site Number 643030, Moscow
Investigational Site Number 642022, Târgovişte
Investigational Site Number 643032, Saint Petersburg
Investigational Site Number 643017, Kemerovo
Investigational Site Number 642006, Brăila
Investigational Site Number 840154, Boston
Investigational Site Number 032006, Caba
Investigational Site Number 032010, Ramos Mejía
Investigational Site Number 032013, Rosario
Investigational Site Number 032015, San Fernando
Investigational Site Number 642010, Bucharest
Investigational Site Number 076001, Curitiba
Investigational Site Number 076030, São José do Rio Preto
Investigational Site Number 203010, Prague
Investigational Site Number 246001, Helsinki
Investigational Site Number 528010, Amsterdam
Investigational Site Number 528001, Leiden
Investigational Site Number 616019, Bydgoszcz
Investigational Site Number 616054, Bytom
Investigational Site Number 616030, Lublin
Investigational Site Number 616031, Warsaw
Investigational Site Number 616017, Warsaw
Investigational Site Number 642021, Bucharest
Investigational Site Number 642001, Bucharest
Investigational Site Number 642020, Bucharest
Investigational Site Number 724020, Barcelona
Investigational Site Number 752004, Malmo
Investigational Site Number 752002, Uppsala
Investigational Site Number 826004, Doncaster
Investigational Site Number 826006, Edinburgh
Investigational Site Number 826001, Leeds
Investigational Site Number 826002, London
Investigational Site Number 826005, Southampton
Investigational Site Number 826025, Wigan
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY